Glycans Marker for Gastric Cancer
A team of researchers from the University of California Davis (California, USA) in collaboration with scientists in Mexico and South Korea have performed liquid chromatography–mass spectrometry (LC–MS) to find that sugars added to proteins could be an indicator of gastric cancer.
A team of researchers from the University of California Davis (California, USA) in collaboration with scientists in Mexico and South Korea have performed liquid chromatography–mass spectrometry (LC–MS) to find that sugars added to proteins could be an indicator of gastric cancer.
The study published in the journal Cancer Prevention Research suggests that glycans (sugars) found in blood serum could be a potential clinical biomarker. The disease kills approximately 700,000 people a year, largely affecting the population of Latin America, Asia, and Eastern Europe. The disease is often the result of a Helicobacter pylori infection, which can also result in asymptomatic gastritis and duodenal ulcers. However, there is no definitive test to determine whether or not the infection will lead to the onset of gastric cancer.
Glycans are added to proteins via the process of glycosylation, that is in a sense the postal service of the cell. The addition of glycans to a protein can be regulatory, in the case of an enzyme, or can act to direct it through the membrane transport system so that it reaches its target destination in the cell. This can be misregulated in some cancers, disrupting regular cell function.
The researchers were interested to learn if the level of glycans in blood serum varied between patients with gastritis, ulcers, or cancer. LC–MS was performed on 72 samples taken from patients in Mexico City. There were 19 significant changes in glycan levels, with three that could be used to differentiate between gastric cancer and gastritis.
Jay Solnick, lead author and professor at the Center for Comparative Medicine at UC Davis, said: “We showed statistically significant differences between the serum glycan profiles of patients with gastric cancer and those with gastritis.” He added: “This is the first time anyone has looked at whether serum glycans could be used to detect gastric cancer.” The next step for the researchers is to use this statistic difference to develop a diagnostic test. - —B.D.
DOI: 10.1158/1940-6207
This article first appeared in The Column. Click here to view that issue.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
